Picture of Dynavax Technologies logo

DVAX — Dynavax Technologies News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareBalancedMid CapHigh Flyer

Dynavax Technologies Corp expected to post earnings of 43  cents a share - Earnings Preview

* Dynavax Technologies Corp  DVAX.OQ   DVAX.O  is expected
to show
a fall in quarterly revenue when it reports  results on February
23. 
    * The Emeryville California-based  company is expected to
report 
a 7.9% decrease in revenue to $179.603 million from $195.07
million a year ago, according to the mean estimate from 5
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Dynavax
Technologies Corp
is for earnings of 43 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Dynavax
Technologies Corp is $22​, above​ its last closing price
of $10.73. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  0.34        0.33       0.43      Beat    31.3
 Jun. 30 2022  0.22        0.22       0.87      Beat    295.5
 Mar. 31 2022  0.24        0.24       0.22      Missed  -8.3​
 Dec. 31 2021  0.61        0.64       0.55      Missed  -14.1
 ​​Sep.        0.03        0.05       -0.24     Missed  -625.5
 30 2021                                                
 Jun. 30 2021  -0.05       -0.04      0.02      Beat    155.1​
 Mar. 31 2021  -0.01       -0.02      0.01      Beat    150
 Dec. 31 2020  -0.24       -0.24      -0.14     Beat    42.5
 This summary was machine generated February 22 at 03:01 GMT. 
All figures in US dollars  unless otherwise stated

Recent news on Dynavax Technologies

See all news